FibroGen Inc (FGEN)
1.21
+0.06
(+5.22%)
USD |
NASDAQ |
May 31, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
FibroGen Enterprise Value: 56.95M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 56.95M |
| May 30, 2024 | 50.98M |
| May 29, 2024 | 52.97M |
| May 28, 2024 | 63.91M |
| May 24, 2024 | 65.90M |
| May 23, 2024 | 63.91M |
| May 22, 2024 | 58.94M |
| May 21, 2024 | 54.96M |
| May 20, 2024 | 55.95M |
| May 17, 2024 | 55.95M |
| May 16, 2024 | 59.93M |
| May 15, 2024 | 54.96M |
| May 14, 2024 | 53.96M |
| May 13, 2024 | 56.95M |
| May 10, 2024 | 51.97M |
| May 09, 2024 | 57.94M |
| May 08, 2024 | 48.99M |
| May 07, 2024 | 72.86M |
| May 06, 2024 | 51.97M |
| May 03, 2024 | 49.98M |
| May 02, 2024 | 48.99M |
| May 01, 2024 | 52.97M |
| April 30, 2024 | 47.99M |
| April 29, 2024 | 45.01M |
| April 26, 2024 | 40.03M |
| Date | Value |
|---|---|
| April 25, 2024 | 38.04M |
| April 24, 2024 | 34.49M |
| April 23, 2024 | 43.02M |
| April 22, 2024 | 49.98M |
| April 19, 2024 | 50.98M |
| April 18, 2024 | 52.97M |
| April 17, 2024 | 62.91M |
| April 16, 2024 | 65.90M |
| April 15, 2024 | 66.89M |
| April 12, 2024 | 65.90M |
| April 11, 2024 | 71.87M |
| April 10, 2024 | 78.83M |
| April 09, 2024 | 86.79M |
| April 08, 2024 | 98.72M |
| April 05, 2024 | 97.73M |
| April 04, 2024 | 93.75M |
| April 03, 2024 | 82.81M |
| April 02, 2024 | 151.45M |
| April 01, 2024 | 171.34M |
| March 31, 2024 | 170.35M |
| March 28, 2024 | 110.43M |
| March 27, 2024 | 133.14M |
| March 26, 2024 | 119.32M |
| March 25, 2024 | 139.07M |
| March 22, 2024 | 133.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-145.12M
Minimum
Sep 22 2023
4.434B
Maximum
Feb 12 2021
1.588B
Average
1.296B
Median
Enterprise Value Benchmarks
| Annovis Bio Inc | 70.04M |
| Emergent BioSolutions Inc | 1.126B |
| Vertex Pharmaceuticals Inc | 107.33B |
| Geron Corp | 1.745B |
| Nanoviricides Inc | 25.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.93M |
| Revenue (Quarterly) | 55.90M |
| Total Expenses (Quarterly) | 86.96M |
| EPS Diluted (Quarterly) | -0.33 |
| Gross Profit Margin (Quarterly) | 53.93% |
| Profit Margin (Quarterly) | -58.91% |
| Earnings Yield | -202.5% |
| Normalized Earnings Yield | -194.10 |